Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.53 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1159366 | 0.87 | SMAD3 (0.58) | HSD17B10HPGDKDM4EMAPTDAO | |
| SCHEMBL3641212 | 0.84 | EIF4A3 (0.56) | HSD17B10HPGDKDM4EMAPTDAO | |
| SCHEMBL1156509 | 0.79 | ALOX15 (0.64) | HSD17B10HPGDKDM4EMAPTCA2 | |
| SCHEMBL3627970 | 0.76 | HSD17B10 (0.59) | HSD17B10HPGDKDM4EMAPTDAO | |
| SCHEMBL8277574 | 0.74 | CA2 (0.47) | HSD17B10HPGDKDM4EMAPTSMAD3 | |
| SCHEMBL3016664 | 0.74 | SMAD3 (0.73) | HSD17B10HPGDKDM4EMAPTDAO | |
| SCHEMBL30445643 | 0.74 | HSD17B10 (0.61) | HSD17B10HPGDKDM4EMAPTDAO | |
| SCHEMBL69851 | 0.74 | HSD17B10 (0.61) | HSD17B10HPGDKDM4EMAPTDAO | |
| SCHEMBL327063 | 0.73 | HSD17B10 (0.56) | HSD17B10HPGDKDM4EMAPTDAO | |
| SCHEMBL19065049 | 0.73 | CA1 (0.70) | KDM4EMAPTCA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776106-B1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMA (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8211935-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7888384-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-08 | — | — | US | disclosed |
| US-7569604-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1776106-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060074076-A1 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006010008-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | HSD17B10 3615/4885HPGD 603/4885KDM4E 3067/4885 |
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | HSD17B10 3615/4885HPGD 603/4885KDM4E 3067/4885 |
| US-20060074076-A1 | Heterocyclic derivatives for modulation of calcium channels | CACNA1D, ORAI1, CACNA1C | HSD17B10 3615/4885HPGD 603/4885KDM4E 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.